Cytokinetics Stock Guidance | NASDAQ:CYTK

Comments

Cytokinetics Inc Stock Guidance

CYTKNASDAQ

Trade with Public

$65.46

0.040.06%

Last update: Apr 17, 10:31 AM

Overview News Earnings OptionsGuidanceAnalyst Ratings Insider Trades Short Interest Government Trades Stock Report

Cytokinetics (CYTK) last issued guidance on February 27, 2024 for fiscal year 2024. The company guided revenue in the range of $3.00M - $5.00M for the period.

Compared to prior guidance, Cytokinetics lowered its revenue forecast from a prior range of $5.00M - $5.00M.

Cytokinetics has issued 2 guidance updates between March 1, 2023 and February 27, 2024. During this period, the company lowered its outlook 1 time, signaling management's revised expectations.

Latest Guidance Date

Feb 27, 2024

Guidance Period

Full Year 2024

Revenue Guidance Range

$3.00M - $5.00M

Cytokinetics Guidance History

Review all historical guidance issued by Cytokinetics, including EPS and revenue forecasts across quarterly and annual periods.

Loading calendar...

FAQ

What is the most recent guidance for Cytokinetics (CYTK)?

The most recent guidance for Cytokinetics (CYTK) was reported on February 27, 2024 for the fiscal year 2024. Cytokinetics forecasted revenue between $3.00M and $5.00M for the period.

What revenue range did Cytokinetics (CYTK) guide for?

Cytokinetics (CYTK) guided revenue in the range of $3.00M to $5.00M for the fiscal year 2024.

Did Cytokinetics (CYTK) raise or lower guidance?

Cytokinetics (CYTK) lowered its revenue guidance from a prior range of $5.00M - $5.00M to $3.00M - $5.00M for the fiscal year 2024.

When did Cytokinetics (CYTK) last issue guidance?

Cytokinetics (CYTK) last issued guidance on February 27, 2024 for the fiscal year 2024.

People Also Watch

Cogent Biosciences Inc

NASDAQ:COGT

$37.06

2.40%

Neurocrine Biosciences Inc

NASDAQ:NBIX

$130.22

1.41%

Centessa Pharmaceuticals PLC

NASDAQ:CNTA

$39.47

-0.15%

Ionis Pharmaceuticals Inc

Protagonist Therapeutics Inc